Lucid Diagnostics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LUCD research report →
Companywww.luciddx.com
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
- CEO
- Lishan Aklog
- IPO
- 2021
- Employees
- 72
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $102.30M
- P/E
- -2.26
- P/S
- 19.93
- P/B
- 25.49
- EV/EBITDA
- -2.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -40.03%
- Op Margin
- -959.64%
- Net Margin
- -876.72%
- ROE
- -370.21%
- ROIC
- -159.95%
Growth & Income
- Revenue
- $4.71M · 8.28%
- Net Income
- $-58,010,000 · -27.41%
- EPS
- $-0.69 · 34.29%
- Op Income
- $-49,640,000
- FCF YoY
- -103693.60%
Performance & Tape
- 52W High
- $1.70
- 52W Low
- $0.91
- 50D MA
- $1.17
- 200D MA
- $1.16
- Beta
- 1.10
- Avg Volume
- 790.11K
Get TickerSpark's AI analysis on LUCD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 23, 26 | Lee Victoria Tou-ho | other | 100,000 |
| Mar 23, 26 | Lee Victoria Tou-ho | other | 0 |
| Feb 20, 26 | Aklog Lishan | other | 2,170,000 |
| Feb 20, 26 | Matheis Dennis | other | 123,000 |
| Feb 20, 26 | White Debra | other | 123,000 |
| Feb 20, 26 | Sparks Ronald M | other | 123,000 |
| Feb 20, 26 | SOKOLOV JACQUE J | other | 123,000 |
| Feb 20, 26 | PALUMBO JOHN R | other | 123,000 |
| Feb 20, 26 | Lapidus Stanley | other | 123,000 |
| Feb 20, 26 | Cox James L | other | 123,000 |
Our LUCD Coverage
We haven't published any research on LUCD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LUCD Report →